Execution of the Medium-Term Management Plan "PROGRESS 3"
First written in FY2016. 23 of 28 entries say "Restated". Latest entry: 2026-05-12.
No other company in this theme has enough history to compare yet.
- 2026-05-12AdvancedEarnings presentation
「Beyond 80 growth strategy — progress in the first year」
Progress on Beyond 80 was presented by comparing first-year results with the final targets for fiscal 2029. - FY2025ReframedAnnual report
「We launched the new 5-year medium-term management plan “Beyond 80” in April 2025. Amid a rapidly changing business environment, Beyond 80 aims to achieve sustainable growth as a drug discovery and R&D-driven company in order to realize our management philosophy. As the vision we aim to achieve in 10 years, in fiscal 2034, we first established the following targets.」
The company changed from the medium-term management plan “PEGASUS” to the new 5-year medium-term plan “Beyond 80,” which began in fiscal 2025. It presented the vision for 10 years ahead and 5 issues as the new planning framework. - FY2024RestatedAnnual report
「In order to achieve sustainable growth as a drug discovery and R&D-driven company, we launched the 5-year medium-term management plan “PEGASUS” in April 2020 and are addressing the following 4 issues.」
The 4 issues under “PEGASUS” remain domestic sales, overseas revenue, the development pipeline and strengthening the management foundation. - FY2024-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2023-Q3RestatedAnnual report
「There were no material changes during the cumulative 3rd quarter of the consolidated fiscal year to the Group’s management policies, management strategies or other related matters.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2023-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2022RestatedAnnual report
「In order to achieve sustainable growth as a drug discovery and R&D-driven company, we launched the 5-year medium-term management plan “PEGASUS” in April 2020 and are addressing the following 4 issues.」
The company reconfirmed the 5-year plan “PEGASUS,” launched in April 2020, and its 4 issues: domestic sales, overseas revenue, the development pipeline and the management foundation. - FY2022-Q3RestatedAnnual report
「There were no material changes during the cumulative 3rd quarter of the consolidated fiscal year to the Group’s management policies, management strategies or other related matters.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2022-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2021-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2021-Q1RestatedAnnual report
「There were no material changes during the cumulative first quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2020ReframedAnnual report
「In light of these changes in the domestic and overseas business environment, we decided to conduct our business activities under a new management strategy in order to achieve sustainable growth as a drug discovery and R&D-driven company. We ended the previous 5-year medium-term management plan after 3 years, launched the new 5-year medium-term management plan “PEGASUS” in April 2020, and will address the following 4 issues.」
The company explicitly stated that it would change from the medium-term management plan “Co-Creation” to the new 5-year medium-term management plan “PEGASUS.” The new framework consists of 4 issues: domestic sales, overseas revenue, the development pipeline and the management foundation. - FY2020-Q3RestatedAnnual report
「There were no material changes during the cumulative 3rd quarter of the consolidated fiscal year to the Group’s management policies, management strategies or other related matters.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2020-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2020-Q1RestatedAnnual report
「There were no material changes during the cumulative first quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2019RestatedAnnual report
「Under the medium-term management plan “Co-Creation,” launched in fiscal 2017, we will strengthen our business foundation for stable future growth under the following basic policies.」
“Co-Creation,” which began in fiscal 2017 and has a 5-year execution period, continues to serve as the framework for our medium-term strategy. - FY2019-Q3RestatedAnnual report
「There were no material changes during the cumulative 3rd quarter of the consolidated fiscal year to the Group’s management policies, management strategies or other related matters.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2019-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2019-Q1RestatedAnnual report
「There were no material changes during the cumulative first quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2018RestatedAnnual report
「Under the medium-term management plan “Co-Creation,” which began in fiscal 2017 and has a 5-year execution period, we will focus on the following 8 issues to be addressed and on achieving them at an early stage.」
The annual report reconfirmed the plan’s 5-year execution period for “Co-Creation” and its 8 issues to be addressed. - FY2018-Q3RestatedAnnual report
「There were no material changes during the cumulative 3rd quarter of the consolidated fiscal year to the Group’s management policies, management strategies or other related matters.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2018-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The Group reconfirms that there were no material changes to its management policies or management strategies. - FY2018-Q1RestatedAnnual report
「There were no material changes during the cumulative first quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」
The filing states that there have been no material changes to the management policies or management strategies. - FY2017ReframedAnnual report
「Under the medium-term management plan “Co-Creation,” launched in fiscal 2017, we will strengthen our business foundation for stable future growth under the following basic policies.」
The medium-term plan changed from the previous medium-term management plan “PROGRESS 3” to “Co-Creation,” which began in fiscal 2017. - FY2017-Q3RestatedAnnual report
「There were no material changes to the issues to be addressed by the Group during the cumulative third quarter of the current fiscal year.」
The company states that there have been no material changes in the issues to be addressed. - FY2017-Q2RestatedAnnual report
「There were no material changes to the issues to be addressed by the Group during the cumulative second quarter of the current fiscal year.」
The company states that there have been no material changes in the issues to be addressed. - FY2017-Q1RestatedAnnual report
「There were no material changes to the issues to be addressed by the Group during the cumulative first quarter of the current fiscal year.」
It stated that there were no material changes to the issues to be addressed identified in the previous fiscal year. - FY2016First statedAnnual report
「Under the medium-term management plan “PROGRESS 3,” covering the period from fiscal 2014 through fiscal 2016, we identified the following 6 items as issues to be addressed and will continue to focus on achieving them at an early stage.」
The 6 issues identified are the product portfolio, clinical development, domestic sales, overseas expansion, production structure and healthcare business.